NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Maze Therapeutics MAZE

Maze Therapeutics listed on Nasdaq on 31 Jan 2025 and is not in the S&P 500. It is worth $1.8 billion. Its board has 12 directors, 6 of them independent. 5 other officers are on file. At 30 Jun 2026, Frazier Life Sciences Management was its largest institutional holder, with 9.1% of the company.

Chair
Herve Hoppenot
Listed
31 Jan 2025 on Nasdaq
Headquarters
South San Francisco, CA
Market cap
$1.8B
19 Nov 2026 close
Price to sales
10.6
On fiscal 2024 revenue

Financials

Financial history

Twelve months to 31 Mar 2026, from Maze Therapeutics' quarterly filings.

Quarters since Jun 2024

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jun 2024 to Mar 2026

Not reported for enough quarters.

Maze Therapeutics' market cap since January 2025

Marked weeks are changes in the share count, such as a merger, not market moves.

Weekly, up to 13 Nov 2026

Apr 2025JulOctJan 2026AprJulOct$1.9B

Board and leadership

Board and officers

2 people here also hold roles at other S&P 500 companies.

Board from the proxy filed 28 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (12)
Herve HoppenotChairIndependent 路 since 2025 路 AuditFormer Chief Executive Officer, Incyte CorporationOther boards: Incyte and Bicycle TherapeuticsChair2025YesAudit66
Nancy C. AndrewsDirectorAlso at Charles River LaboratoriesDirector
Nancy C. Andrews, M.D., Ph.D.DirectorIndependent 路 since 2021 路 Compensation, Research and DevelopmentExecutive Vice President and Chief Scientific Officer, Boston Children's HospitalOther boards: Novartis and Charles River LaboratoriesDirector2021YesCompensation, Research and Development67
Jason Coloma, Ph.D.Director and CEONot independent 路 since 2019Director and CEO2019No50
Charles J. HomcyDirectorNot independent 路 since 2018 路 Nominating and Corporate Governance, Research and DevelopmentCo-founder, Maze Therapeutics, Inc. and BridgeBio Pharma, Inc.Other boards: BridgeBio PharmaDirector2018NoNominating and Corporate Governance, Research and Development77
Paula A. JohnsonDirectorAlso at Johnson & JohnsonDirector
Sophie KornowskiDirectorDirector
Neil Kumar, Ph.D.DirectorIndependent 路 since 2026Chief Executive Officer, BridgeBio Pharma, Inc.Other boards: BridgeBio Pharma, Eidos Therapeutics, BridgeBio Oncology Therapeutics and LianBioDirector2026Yes47
Jonathan E. LimDirectorIndependent 路 since 2019 路 Compensation (chair)Chairman and Chief Executive Officer, Erasca, Inc.; Venture Partner, ARCH Venture Partners, LLCOther boards: Erasca and Boundless BioDirector2019YesCompensation (chair)54
Richard H. SchellerDirectorDirector
Richard Scheller, Ph.D.DirectorIndependent 路 since 2019 路 Research and Development (chair)Chair of Research and Development, BridgeBio Pharma Inc.Other boards: 23andMe and AlectorDirector2019YesResearch and Development (chair)72
Daniel K. SpiegelmanDirectorIndependent 路 since 2020 路 Audit (chair), Nominating and Corporate GovernanceCorporate Director; Former Executive Vice President and Chief Financial Officer, Biomarin Pharmaceuticals Inc.Other boards: Spruce Biosciences, Kyverna Therapeutics and vTv TherapeuticsDirector2020YesAudit (chair), Nominating and Corporate Governance67
Officers (5)
Misbah TahirChief Financial OfficerLast filed 3 Mar 2026Chief Financial Officer
Harold BernsteinPresident, R&D & CMOLast filed 8 Sep 2026President, R&D & CMO
Jason V. ColomaChief Executive OfficerLast filed 4 Sep 2026Chief Executive Officer
Phillips CourtneyGC and Corp. SecretaryLast filed 4 Sep 2026GC and Corp. Secretary
Atul DandekarCsboLast filed 4 Sep 2026Csbo

Owners and trading

Largest institutional holders

Each fund group's share of Maze Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Frazier Life Sciences Management9.1%
  • Trv GP Iv8.1%
  • Arch Venture Management7.4%
  • Deep Track Capital6.7%
  • BlackRock6.3%

These five hold 37.7% of Maze Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $25.0 million of stock in 55 sales and made no open-market purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
2 Nov 2026SaleJason V. ColomaChief Executive OfficerChief Executive OfficerSale34,501$1.0M
29 Oct 2026SaleAtul DandekarCsboCsboSale7,500$241K
1 Oct 2026SaleJason V. ColomaChief Executive OfficerChief Executive OfficerSale34,501$932K
1 Oct 2026SaleHarold BernsteinPresident, R&D & CMOPresident, R&D & CMOSale16,141$435K
29 Sep 2026SaleAtul DandekarCsboCsboSale7,500$203K
4 Sep 2026SaleHarold BernsteinPresident, R&D & CMOPresident, R&D & CMOSale9,705$254K
3 Sep 2026SaleJason V. ColomaChief Executive OfficerChief Executive OfficerSale11,411$297K
3 Sep 2026SaleHarold BernsteinPresident, R&D & CMOPresident, R&D & CMOSale5,189$135K
3 Sep 2026SaleAtul DandekarCsboCsboSale3,243$84K
3 Sep 2026SalePhillips CourtneyGC and Corp. SecretaryGC and Corp. SecretarySale2,012$52K

Showing 10 of 55 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

4 departures and 7 appointments of directors and officers and 7 large insider sales in the last two years.

Left the company or board 4Appointed 7WARN layoff notices 0Large insider sales 7Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Maze Therapeutics' insider sales.

Events, newest first

Showing 8 of 18 events

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.